Novo Nordisk CEO on disappointing Rybelsus sales: Influenced by lockdown
Sales of diabetes tablet Rybelsus have been significantly lower than what analysts had predicted, according to Wednesday’s quarterly report from Novo Nordisk. CEO Lars Fruergaard Jørgensen thinks this is due to lockdowns.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
In spite of GLP-1 sales increasing overall, Novo Nordisk's diabetes tablet Rybelsus sold for significantly less than what industry analysts had forecast for the first three months of the year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk beats expectations – upgrades outlook
For subscribers
Chinese authorities have approved Novo Nordisk's Ozempic
For subscribers
Analyst: Novo Nordisk's year may start with zero growth
For subscribers
.jpg&w=384&q=75)
